{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:49:50Z","timestamp":1787014190971,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mycosis fungoides (MF) is a subtype of cutaneous T\u2010cell lymphoma (CTCL). Topical or systemic treatment with psoralen, such as 8\u2010methoxypsoralen (8\u2010MOP), followed by ultraviolet A (UVA) irradiation (PUVA therapy) is an effective phototherapy for early\u2010stage MF. However, the efficacy of PUVA therapy for advanced\u2010stage MF is not satisfactory, and the ideal combination partner for PUVA therapy has not yet been found. In this study, we developed a new mouse model of CTCL in which efficacy of PUVA was detected and further evaluated the efficacy of combination treatment of PUVA and mogamulizumab, an anti\u2010CCR4 monoclonal antibody. Cytotoxicity of PUVA therapy against HH cells, a CTCL cell line, was observed in vitro. The cytotoxicity was dependent on both 8\u2010MOP and UVA. Using HH cells, we developed a mouse model in which HH cells were subcutaneously inoculated in the ear. In this model, PUVA therapy suppressed tumour growth with statistical significance, while 8\u2010MOP or UVA alone did not. Combination therapy of PUVA and mogamulizumab showed greater antitumor activity than either monotherapy with statistical significance. In the histological analysis of the tumour tissue, PUVA accelerated tumour necrosis and then induced the infiltration inflammatory cells in the necrotic area, suggesting that these cells served as effector cells for mogamulizumab. This combination therapy is expected to be a beneficial option for CTCL therapy.<\/jats:p>","DOI":"10.1111\/exd.14641","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T04:02:02Z","timestamp":1657252922000},"page":"1693-1698","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel mouse model of cutaneous T\u2010cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-0940","authenticated-orcid":false,"given":"Keiko","family":"Nakahashi","sequence":"first","affiliation":[{"name":"Translational Research Management Office, Translational Research Unit, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Nihira","sequence":"additional","affiliation":[{"name":"Toxicological Research Laboratories, Translational Research Unit, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Biomedical Research Laboratories 2, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishii","sequence":"additional","affiliation":[{"name":"Biomedical Research Laboratories 2, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Masuda","sequence":"additional","affiliation":[{"name":"Biomedical Research Laboratories 1, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Biomedical Research Laboratories 2, R&amp;D Division Kyowa Kirin Co., Ltd.  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0022"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-611830"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(98)00064-4"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.033"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2697"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.06.005"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490218"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-017-1749-9"},{"issue":"3","key":"e_1_2_11_11_1","first-page":"814","article-title":"Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors","volume":"50","author":"Jain RK","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102372"},{"issue":"7","key":"e_1_2_11_13_1","first-page":"e1011524\u20101\u20102","article-title":"Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab","volume":"4","author":"Ni X","year":"2015","journal-title":"Onco Targets Ther"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001587"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01642.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12014809"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/exd.14641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.14641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T21:38:49Z","timestamp":1692653929000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.14641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/exd.14641"],"URL":"https:\/\/doi.org\/10.1111\/exd.14641","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"2021-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}